296 related articles for article (PubMed ID: 32975358)
1. Fitness of influenza A and B viruses with reduced susceptibility to baloxavir: A mini-review.
Abed Y; Saim-Mamoun A; Boivin G
Rev Med Virol; 2021 May; 31(3):e2175. PubMed ID: 32975358
[TBL] [Abstract][Full Text] [Related]
2. Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice.
Abed Y; Fage C; Checkmahomed L; Venable MC; Boivin G
Antiviral Res; 2020 Jul; 179():104807. PubMed ID: 32343991
[TBL] [Abstract][Full Text] [Related]
3. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.
Takashita E; Daniels RS; Fujisaki S; Gregory V; Gubareva LV; Huang W; Hurt AC; Lackenby A; Nguyen HT; Pereyaslov D; Roe M; Samaan M; Subbarao K; Tse H; Wang D; Yen HL; Zhang W; Meijer A
Antiviral Res; 2020 Mar; 175():104718. PubMed ID: 32004620
[TBL] [Abstract][Full Text] [Related]
4. The active form of the influenza cap-snatching endonuclease inhibitor baloxavir marboxil is a tight binding inhibitor.
Todd B; Tchesnokov EP; Götte M
J Biol Chem; 2021; 296():100486. PubMed ID: 33647314
[TBL] [Abstract][Full Text] [Related]
5. Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza.
Shirley M
Drugs; 2020 Jul; 80(11):1109-1118. PubMed ID: 32601915
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection.
Taniguchi K; Ando Y; Kobayashi M; Toba S; Nobori H; Sanaki T; Noshi T; Kawai M; Yoshida R; Sato A; Shishido T; Naito A; Matsuno K; Okamatsu M; Sakoda Y; Kida H
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062315
[TBL] [Abstract][Full Text] [Related]
7. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.
Noshi T; Kitano M; Taniguchi K; Yamamoto A; Omoto S; Baba K; Hashimoto T; Ishida K; Kushima Y; Hattori K; Kawai M; Yoshida R; Kobayashi M; Yoshinaga T; Sato A; Okamatsu M; Sakoda Y; Kida H; Shishido T; Naito A
Antiviral Res; 2018 Dec; 160():109-117. PubMed ID: 30316915
[TBL] [Abstract][Full Text] [Related]
8. A Comparison of the Frequency of Prescription and Pharmacy Revisits between Baloxavir Marboxil and Neuraminidase Inhibitors in Influenza-Infected Pediatric Patients during the 2019-2020 Influenza Season.
Norikoshi Y; Ikeda T; Sasahara K; Hamada M; Torigoe E; Nagae M; Tashiro T; Horio F; Saruwatari J; Uchida Y; Anraku M
Biol Pharm Bull; 2020; 43(12):1960-1965. PubMed ID: 33268716
[TBL] [Abstract][Full Text] [Related]
9. A novel E198K substitution in the PA gene of influenza A virus with reduced susceptibility to baloxavir acid.
Takizawa N; Momose F
Arch Virol; 2022 Jul; 167(7):1565-1570. PubMed ID: 35511288
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Baloxavir Marboxil and Peramivir for the Treatment of High Pathogenicity Avian Influenza in Chickens.
Twabela A; Okamatsu M; Matsuno K; Isoda N; Sakoda Y
Viruses; 2020 Dec; 12(12):. PubMed ID: 33302389
[TBL] [Abstract][Full Text] [Related]
11. Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil.
Nakauchi M; Takashita E; Fujisaki S; Shirakura M; Ogawa R; Morita H; Miura H; Saito S; Watanabe S; Odagiri T; Kageyama T
Influenza Other Respir Viruses; 2020 Jul; 14(4):436-443. PubMed ID: 32064779
[TBL] [Abstract][Full Text] [Related]
12. The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets.
Kitano M; Matsuzaki T; Oka R; Baba K; Noda T; Yoshida Y; Sato K; Kiyota K; Mizutare T; Yoshida R; Sato A; Kamimori H; Shishido T; Naito A
Influenza Other Respir Viruses; 2020 Nov; 14(6):710-719. PubMed ID: 32533654
[TBL] [Abstract][Full Text] [Related]
13. Influenza A virus polymerase acidic protein E23G/K substitutions weaken key baloxavir drug-binding contacts with minimal impact on replication and transmission.
Jones JC; Zagribelnyy B; Pascua PNQ; Bezrukov DS; Barman S; Okda F; Webby RJ; Ivanenkov YA; Govorkova EA
PLoS Pathog; 2022 Jul; 18(7):e1010698. PubMed ID: 35830486
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive assessment of amino acid substitutions in the trimeric RNA polymerase complex of influenza A virus detected in clinical trials of baloxavir marboxil.
Hashimoto T; Baba K; Inoue K; Okane M; Hata S; Shishido T; Naito A; Wildum S; Omoto S
Influenza Other Respir Viruses; 2021 May; 15(3):389-395. PubMed ID: 33099886
[TBL] [Abstract][Full Text] [Related]
15. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020.
Govorkova EA; Takashita E; Daniels RS; Fujisaki S; Presser LD; Patel MC; Huang W; Lackenby A; Nguyen HT; Pereyaslov D; Rattigan A; Brown SK; Samaan M; Subbarao K; Wong S; Wang D; Webby RJ; Yen HL; Zhang W; Meijer A; Gubareva LV
Antiviral Res; 2022 Apr; 200():105281. PubMed ID: 35292289
[TBL] [Abstract][Full Text] [Related]
16. Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility.
Jones JC; Pascua PNQ; Fabrizio TP; Marathe BM; Seiler P; Barman S; Webby RJ; Webster RG; Govorkova EA
Proc Natl Acad Sci U S A; 2020 Apr; 117(15):8593-8601. PubMed ID: 32217734
[TBL] [Abstract][Full Text] [Related]
17. Early combination treatment with baloxavir and peramivir for hospitalized adults with influenza A in Yokohama, Japan.
Yoshimura Y; Sasaki H; Horiuchi H; Miyata N; Kawakami C; Usuku S; Tachikawa N
Eur J Clin Microbiol Infect Dis; 2020 Sep; 39(9):1637-1640. PubMed ID: 32291543
[TBL] [Abstract][Full Text] [Related]
18. The impact of PA/I38 substitutions and PA polymorphisms on the susceptibility of zoonotic influenza A viruses to baloxavir.
Taniguchi K; Noshi T; Omoto S; Sato A; Shishido T; Matsuno K; Okamatsu M; Krauss S; Webby RJ; Sakoda Y; Kida H
Arch Virol; 2024 Jan; 169(2):29. PubMed ID: 38216710
[TBL] [Abstract][Full Text] [Related]
19. Development of cycling probe based real-time PCR methodology for influenza A viruses possessing the PA/I38T amino acid substitution associated with reduced baloxavir susceptibility.
Osada H; Chon I; Phyu WW; Wagatsuma K; Nagata N; Kawashima T; Sato I; Saito T; Kodo N; Masaki H; Asoh N; Tsuchihashi Y; Shirahige Y; Ono Y; Shimada Y; Hamabata H; Saito K; Saito R
Antiviral Res; 2021 Apr; 188():105036. PubMed ID: 33577807
[TBL] [Abstract][Full Text] [Related]
20. Neuraminidase inhibitors and single dose baloxavir are effective and safe in uncomplicated influenza: a meta-analysis of randomized controlled trials.
Tejada S; Tejo AM; Peña-López Y; Forero CG; Corbella X; Rello J
Expert Rev Clin Pharmacol; 2021 Jul; 14(7):901-918. PubMed ID: 33861168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
